{"id":7244,"date":"2021-01-05T10:02:17","date_gmt":"2021-01-05T09:02:17","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=7244"},"modified":"2021-02-01T10:01:46","modified_gmt":"2021-02-01T09:01:46","slug":"andera-partners-cede-arvelle-therapeutics-a-angelini-pharma","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/","title":{"rendered":"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma"},"content":{"rendered":"

Andera Partners<\/strong>, un acteur de premier plan dans le domaine du capital-investissement, via son activit\u00e9 Andera Life Sciences ax\u00e9e sur les investissements dans des soci\u00e9t\u00e9s d\u00e9veloppant des produits th\u00e9rapeutiques et des technologies m\u00e9dicales de pointe, a annonc\u00e9 aujourd’hui que Angelini Pharma, une soci\u00e9t\u00e9 pharmaceutique internationale du groupe priv\u00e9 italien Angelini, a conclu un accord de fusion d\u00e9finitif avec Arvelle Therapeutics, soci\u00e9t\u00e9 du portefeuille de Andera Life Sciences. Selon l’accord, Arvelle Therapeutics, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e en Suisse qui se concentre sur la mise \u00e0 disposition de traitements innovants pour les patients souffrant de troubles du syst\u00e8me nerveux central (SNC), sera acquise dans le cadre d’une transaction enti\u00e8rement en cash pour une valeur totale pouvant atteindre 960 millions de dollars. Apr\u00e8s l’approbation r\u00e9glementaire, un premier paiement de 610 millions de dollars sera op\u00e9r\u00e9. Par la suite, et sous r\u00e9serve que le c\u00e9nobamate atteigne certains objectifs de revenus, un paiement compl\u00e9mentaire de 350 millions de dollars suppl\u00e9mentaires sera effectu\u00e9.<\/p>\n

Andera Partners avait \u00e9t\u00e9 co-lead de la s\u00e9rie A pour un financement start-up de 207,8 millions de dollars d’Arvelle Therapeutics en f\u00e9vrier 2019 et a rejoint le conseil d’administration de la soci\u00e9t\u00e9. Avec ces fonds, Arvelle a obtenu une licence europ\u00e9enne pour les droits de c\u00e9nobamate de SK BioPharmaceuticals, a pr\u00e9par\u00e9 la soumission r\u00e9glementaire du m\u00e9dicament et a cr\u00e9\u00e9 une structure europ\u00e9enne.<\/p>\n

A la suite de cette acquisition, Angelini Pharma d\u00e9tiendra la licence exclusive pour commercialiser le c\u00e9nobamate dans l’Union europ\u00e9enne et dans d’autres pays de l\u2019Espace Economique Europ\u00e9en (Suisse et Royaume-Uni). Angelini pr\u00e9voit de lancer le c\u00e9nobamate apr\u00e8s avoir re\u00e7u l’approbation de l’Agence europ\u00e9enne des m\u00e9dicaments (EMA), qui est attendue en 2021.<\/p>\n

Le c\u00e9nobamate est une mol\u00e9cule dot\u00e9e d’un double m\u00e9canisme d’action compl\u00e9mentaire unique. Il agit en modulant positivement le canal ionique de l’acide aminobutyrique (GABAA) \u03b3 et en inhibant les courants de sodium \u00e0 tension contr\u00f4l\u00e9e. Les principales conclusions de l’\u00e9tude ont document\u00e9 l’efficacit\u00e9 clinique du c\u00e9nobamate en montrant une r\u00e9duction significativement plus importante de la fr\u00e9quence m\u00e9diane des crises et un plus grand nombre de patients obtenant une r\u00e9duction de 50 % ou plus de la fr\u00e9quence des crises par rapport au groupe placebo.<\/p>\n

Le c\u00e9nobamate est approuv\u00e9 par la Food and Drug Administration (FDA) aux \u00c9tats-Unis en tant que m\u00e9dicament anti-convulsions pour le traitement des crises d’\u00e9pilepsie focales chez les adultes. En 2020, Arvelle a d\u00e9pos\u00e9 une demande d’approbation europ\u00e9enne du c\u00e9nobamate.<\/p>\n

Olivier Litzka, associ\u00e9 chez Andera Life Sciences et membre du conseil d’administration d’Arvelle Therapeutics a comment\u00e9 : \u00ab\u00a0Nous sommes extr\u00eamement heureux, chez Andera Partners, d’avoir contribu\u00e9 \u00e0 l’avancement de ce nouveau m\u00e9dicament important dans le domaine de l’\u00e9pilepsie r\u00e9fractaire. Le management d’Arvelle a fait un travail formidable pour, tout d’abord, cr\u00e9er la soci\u00e9t\u00e9 bas\u00e9e sur le m\u00e9dicament sous licence, attirer l’important tour de financement de 2018 que nous avons co-men\u00e9, construire une grande organisation et, enfin, trouver un excellent partenaire pour la poursuite de l’entr\u00e9e sur le march\u00e9 du c\u00e9nobamate en Europe\u00a0\u00bb.<\/em><\/p>\n

Cette transaction est la deuxi\u00e8me vente industrielle du portefeuille du fonds d\u2019Andera Life Sciences BioDiscovery 5, apr\u00e8s la vente de Corvidia \u00e0 NovoNordisk pour 2,1 milliards de dollars \u00e0 l’\u00e9t\u00e9 2020. Elle s’ajoute aux quatre IPO des soci\u00e9t\u00e9s de BioDiscovery 5 (Axonics, Erytech, LogicBio et Nyxoah), alors que la p\u00e9riode d’investissement du fonds est toujours en cours.<\/p>\n","protected":false},"excerpt":{"rendered":"

Andera Partners, un acteur de premier plan dans le domaine du capital-investissement, via son activit\u00e9 Andera Life Sciences ax\u00e9e sur les investissements dans des soci\u00e9t\u00e9s d\u00e9veloppant des produits th\u00e9rapeutiques et des technologies m\u00e9dicales de pointe, a annonc\u00e9 aujourd’hui que Angelini Pharma, une soci\u00e9t\u00e9 pharmaceutique internationale du groupe priv\u00e9 italien Angelini, a conclu un accord de…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-7244","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\nAndera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners, un acteur de premier plan dans le domaine du capital-investissement, via son activit\u00e9 Andera Life Sciences ax\u00e9e sur les investissements dans des soci\u00e9t\u00e9s d\u00e9veloppant des produits th\u00e9rapeutiques et des technologies m\u00e9dicales de pointe, a annonc\u00e9 aujourd’hui que Angelini Pharma, une soci\u00e9t\u00e9 pharmaceutique internationale du groupe priv\u00e9 italien Angelini, a conclu un accord de...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T09:02:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-01T09:01:46+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma\",\"datePublished\":\"2021-01-05T09:02:17+00:00\",\"dateModified\":\"2021-02-01T09:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\"},\"wordCount\":632,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\",\"name\":\"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2021-01-05T09:02:17+00:00\",\"dateModified\":\"2021-02-01T09:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/","og_locale":"fr_FR","og_type":"article","og_title":"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma - ANDERA PARTNERS","og_description":"Andera Partners, un acteur de premier plan dans le domaine du capital-investissement, via son activit\u00e9 Andera Life Sciences ax\u00e9e sur les investissements dans des soci\u00e9t\u00e9s d\u00e9veloppant des produits th\u00e9rapeutiques et des technologies m\u00e9dicales de pointe, a annonc\u00e9 aujourd’hui que Angelini Pharma, une soci\u00e9t\u00e9 pharmaceutique internationale du groupe priv\u00e9 italien Angelini, a conclu un accord de...","og_url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2021-01-05T09:02:17+00:00","article_modified_time":"2021-02-01T09:01:46+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma","datePublished":"2021-01-05T09:02:17+00:00","dateModified":"2021-02-01T09:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/"},"wordCount":632,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/","url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/","name":"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2021-01-05T09:02:17+00:00","dateModified":"2021-02-01T09:01:46+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-arvelle-therapeutics-a-angelini-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Andera Life Sciences c\u00e8de Arvelle Therapeutics \u00e0 Angelini Pharma"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/7244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=7244"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/7244\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=7244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=7244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}